arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Vericel Corp

VCEL
$45.06 ▲ +0.34 (+0.77%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
19 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Neutral
auto_awesome

Analytical Summary

Vericel Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.3B
Dividend Yield
Revenue Growth 16.5%
Op. Margin 4.0%
ROIC 3.0%
FCF / Share $0.49
Trailing P/E 136.6x
Price / Book 6.4x
FCF Yield 1.1%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$276.26M
↑ +16.5%
Net Income Profit after all expenses
$16.52M
↑ +59.4%
Operating Margin Operating profit as % of sales
4.0%
↑ +109.9% 39th
FCF / Share Free cash flow per share
$0.49
↑ +513.3%
Long-Term Debt Long-term obligations
$6.00K
↓ -85.0%

Health Breakdown

Profitability
50
Returns
53
Financial Health
90
Cash Quality
80

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 69 quarters